Richardpruen (talk | contribs) (→Suggested additions to this page: Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?) |
Richardpruen (talk | contribs) (→Suggested additions to this page: Added to COVID section) |
||
| Line 500: | Line 500: | ||
*Abstract: "SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS). Great efforts are currently being made to block the signal transduction pathway of pro-inflammatory cytokines in order to control this “cytokine storm” and rescue severely affected patients. Consequently, possible treatments for cytokine-mediated hyperinflammation, preferably within approved safe therapies, are urgently being researched to reduce rising mortality. One approach to inhibit proinflammatory cytokine release is to activate the cholinergic anti-inflammatory pathway through nicotinic acetylcholine receptors (α7nAchR). Nicotine, an exogenous α7nAchR agonist, is clinically used in ulcerative colitis to counteract inflammation. We have found epidemiological evidence, based on recent clinical SARS-CoV-2 studies in China, that suggest that smokers are statistically less likely to be hospitalized. In conclusion, our hypothesis proposes that nicotine could constitute a novel potential CRS therapy in severe SARS-CoV-2 patients." | *Abstract: "SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS). Great efforts are currently being made to block the signal transduction pathway of pro-inflammatory cytokines in order to control this “cytokine storm” and rescue severely affected patients. Consequently, possible treatments for cytokine-mediated hyperinflammation, preferably within approved safe therapies, are urgently being researched to reduce rising mortality. One approach to inhibit proinflammatory cytokine release is to activate the cholinergic anti-inflammatory pathway through nicotinic acetylcholine receptors (α7nAchR). Nicotine, an exogenous α7nAchR agonist, is clinically used in ulcerative colitis to counteract inflammation. We have found epidemiological evidence, based on recent clinical SARS-CoV-2 studies in China, that suggest that smokers are statistically less likely to be hospitalized. In conclusion, our hypothesis proposes that nicotine could constitute a novel potential CRS therapy in severe SARS-CoV-2 patients." | ||
*Citation: Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E, Lopez-Najera A, Jimenez-Diaz L, Navarro-Lopez JD, Najera A. Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm. Front Immunol. 2020 Jun 11;11:1359. doi: 10.3389/fimmu.2020.01359. PMID: 32595653; PMCID: PMC7300218. | *Citation: Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E, Lopez-Najera A, Jimenez-Diaz L, Navarro-Lopez JD, Najera A. Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm. Front Immunol. 2020 Jun 11;11:1359. doi: 10.3389/fimmu.2020.01359. PMID: 32595653; PMCID: PMC7300218. | ||
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36650574/ Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?] === | |||
* Nicotine COVID/SARS-CoV-2 interaction mystery takes another turn. | |||
* Non-intrinsic viral nAChR attachment compromises integrative interneuronal communication substantially. This explains the cognitive, neuromuscular and mood impairment, as well as the vegetative symptoms, characterizing post-COVID-19 syndrome. The agonist ligand nicotine shows an up to 30-fold higher affinity to nACHRs than acetylcholine (ACh). | |||
* We therefore hypothesize that this molecule could displace the virus from nAChR attachment and pave the way for unimpaired cholinergic signal transmission. Treating several individuals suffering from post-COVID-19 syndrome with a nicotine patch application, we witnessed improvements ranging from immediate and substantial to complete remission in a matter of days. | |||
* Citation: Leitzke M. Bioelectron Med. 2023 Jan 18;9(1):2. doi: 10.1186/s42234-023-00104-7. PMID: 36650574 Free PMC article. | |||
<br> | <br> | ||
='''Digestive Tract / Bowel'''= <!--T:101--> | ='''Digestive Tract / Bowel'''= <!--T:101--> | ||
| Line 1,312: | Line 1,318: | ||
<br> | <br> | ||
='''Suggested additions to this page'''= | ='''Suggested additions to this page'''= | ||
===2022: [https://assets.researchsquare.com/files/rs-1062121/v1/fb8f5195-4cce-470f-9e09-e752fae3c931.pdf?c=1642705044 Part One: Abuse Liability of Vuse Solo Relative To Combustible Cigarettes And Nicotine Gum]=== | === 2022: [https://assets.researchsquare.com/files/rs-1062121/v1/fb8f5195-4cce-470f-9e09-e752fae3c931.pdf?c=1642705044 Part One: Abuse Liability of Vuse Solo Relative To Combustible Cigarettes And Nicotine Gum] === | ||
===2014: [https://link.springer.com/chapter/10.1007/978-1-4939-1167-7_20 Nicotinic Receptors and Mental Illness]=== | === 2014: [https://link.springer.com/chapter/10.1007/978-1-4939-1167-7_20 Nicotinic Receptors and Mental Illness] === | ||
===2021: [https://pubmed.ncbi.nlm.nih.gov/34757527/ Meta-Analysis on Nicotine's Modulation of HIV-Associated Dementia]=== | ===2021: [https://pubmed.ncbi.nlm.nih.gov/34757527/ Meta-Analysis on Nicotine's Modulation of HIV-Associated Dementia]=== | ||
edits